American Association for the Advancement of Science, Science Translational Medicine, 371(9), 2017
DOI: 10.1126/scitranslmed.aaf5294
Full text: Unavailable
PAR4 inhibition with a reversible small-molecule antagonist is a promising antiplatelet therapy.